Laura A. Pace, MD, PhD
CEO and Co-founder of Metrodora Institute
Chief Medical Officer
Dr. Pace is a physician-scientist with over 20 years of clinical and research experience. She is board-certified in internal medicine, gastroenterology, and autonomic disorders, with advanced training in neurogastroenterology and medical genetics. Dr. Pace is a leading expert in diagnosing and treating patients with complex disorders at the interface of gastroenterology, neurology, immunology, and genetics.
She is a Fellow of the American College of Gastroenterology (ACG) and member of the American Gastroenterological Association (AGA), American Neurogastroenterology and Motility Society (ANMS), American Autonomic Society (AAS), and American Academy of Neurology (AAN).
Her research focuses on neuroimmune axis disorders, mucosal immunology, host-microbiota interactions, and complex genetic conditions. A leader in the rare disease space, Dr. Pace has served as the Co-Lead for of the University of Utah’s NIH Undiagnosed Diseases Network (NIH UDN) clinical site since 2017. She has also served as principal investigator of numerous clinical trials, including the current Argenx Alpha Study, testing a new therapeutic for post-COVID postural orthostatic tachycardia (POTS), for which Metrodora Institute is a clinical trial site.
A fierce patient advocate, Dr. Pace serves as a Medical Board member of Dysautonomia International and Chair of the Gastrointestinal Working Group for the International Consortium on Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders. She has published more than 100 peer-reviewed journal articles and has received research funding from the National Institutes of Health (NIH) and private foundations.